Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

March 22rd, 2023

AUTHORS
Kseniya Petrova-Drus / Mustafa Syed / Wayne Yu / Kasey Hutt / Alyssa M. Zlotnicki / Ying Huang / Monika Kamalska-Cyganik / Lidia Maciag / Meiyi Wang / Yuanyuan G. Ma / Caleb Ho / Christine Moung / Jinjuan Yao / Khedoudja Nafa / Jeeyeon Baik / Chad M. Vanderbilt / Jamal K. Benhamida / Ying Liu / Menglei Zhu / Benjamin Durham / Mark D. Ewalt / Paulo Salazar / Ivelise Rijo / Tessara Baldi / Anthony Mato / Lindsey E. Roeker / Mikhail Roshal / Ahmet Dogan / Maria E. Arcila

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

January 25th, 2024 Leveraging Standardized MRD Assays to Guide CLL Treatment

March 23rd, 2023 Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.